This site is intended for health professionals only

Victory for Merck in Fosamax case


A US woman who claimed Merck and Co’s osteoporosis drug Fosamax caused her serious jaw problems has lost her battle for compensation.

Louise Maley, from Indiana, said she had developed osteonecrosis of the jaw – a form of bone death – as a direct result of taking the treatment for almost eight years.

But a jury in New York found in Merck’s favour, saying that the 69-year-old had multiple conditions with the capacity to cause the disease.

Merck attorney Christy Jones said: “Unfortunately, the plaintiff had multiple medical conditions that cause people to develop the jaw and dental problems she claims she has, regardless of whether they were taking Fosamax.”

The drugmaker faces more than 1,000 other cases linked to jaw damage and dental problems.

Copyright Press Association 2010
Merck & Co

Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine